AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.390
-0.050 (-3.47%)
At close: Mar 28, 2025, 4:00 PM
1.400
+0.010 (0.72%)
After-hours: Mar 28, 2025, 7:51 PM EDT
AN2 Therapeutics Employees
AN2 Therapeutics had 41 employees as of December 31, 2023. The number of employees increased by 5 or 13.89% compared to the previous year.
Employees
41
Change (1Y)
5
Growth (1Y)
13.89%
Revenue / Employee
n/a
Profits / Employee
-$1,251,732
Market Cap
41.84M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 41 | 5 | 13.89% |
Dec 31, 2022 | 36 | 14 | 63.64% |
Dec 31, 2021 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ANTX News
- 5 days ago - AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 27 days ago - AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference - Business Wire
- 4 weeks ago - AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease - Business Wire
- 5 weeks ago - AN2 Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 4 months ago - AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline - Business Wire
- 5 months ago - AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria - Business Wire
- 7 months ago - AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire